Hi! I’m Doug, the founder of Pace Pharmaceuticals. We’re developing drugs for neurological diseases.

We currently have two compound series that have completed the discovery phase for Alzheimer’s disease and schizophrenia, respectively.

• Lead compound #1

  PAC-832

  The world’s first selective small-molecule GalR1 antagonist for Alzheimer’s disease.

  Non-technical overview · Full technical report
• Lead compound #2

  PAC-336

  Selective M4 agonist for schizophrenia.

  Reports in progress

These compounds are now undergoing IND-enabling studies and will enter clinical testing within the next year.